Pharmacology in the era of targeted therapies: The case of PI3K inhibitors Journal Article

   


Authors: Toska, E.; Baselga, J.
Article Title: Pharmacology in the era of targeted therapies: The case of PI3K inhibitors
Abstract: The PI3K pathway is often aberrantly activated in estrogen receptor positive (ER+ ) breast cancer and therapies combining PI3K inhibitors and antiestrogens are under clinical development. Given that many PI3K inhibitors have substantial toxicities with continuous dosing and that alternate dosing schedules are equally active, further clinical exploration is warranted. © 2016 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 22
Issue: 9
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2016-05-01
Start Page: 2099
End Page: 2101
Language: English
DOI: 10.1158/1078-0432.ccr-16-0038
PROVIDER: scopus
PUBMED: 26957555
PMCID: PMC4946572
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84968626459&partnerID=40&md5=7a5d621569ae5dbdc0ea58b13c27de6a
Notes: Article -- Export Date: 2 June 2016 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jose T Baselga
    484 Baselga
  2. Eneda Toska
    30 Toska
Related MSK Work